Skip to main content
Top
Published in: Pituitary 3/2011

01-09-2011

AMP-activated protein kinase regulates normal rat somatotroph cell function and growth of rat pituitary adenomatous cells

Authors: Giovanni Tulipano, Michela Giovannini, Maurizio Spinello, Valeria Sibilia, Andrea Giustina, Daniela Cocchi

Published in: Pituitary | Issue 3/2011

Login to get access

Abstract

AMP-activated protein kinase (AMPK) is activated under conditions that deplete cellular ATP and elevate AMP levels such as glucose deprivation and hypoxia. The AMPK system is primarily thought of as a regulator of metabolism and cell proliferation. Little is known about the regulation and the effects of AMPK in somatotroph cells. We present results from “in vitro” studies showing that AMPK activity has a role in regulating somatotroph function in normal rat pituitary and is a promising target for the development of new pharmacological treatments affecting cell proliferation and viability of pituitary adenomatous cells. In parallel, we show “in vivo” data obtained in the rat suggesting that AMPK is an intracellular transducer that may play a role in mediating the effects of the pharmacological treatment with dexamethasone on somatotrophs. In rat pituitary cell cultures, the AMP analog AICAR induced a rapid and clear-cut activation of AMPK. AICAR decreased GH release and total cellular GH content. An appropriate level of AMPK activation was essential for GH3 adenomatous cells. Remarkably, over-activation by AICAR induced apoptosis of GH3 whereas the AMPK inhibitor compound C was more effective at reducing cell proliferation. The role of endocrine or paracrine factors in regulating AMPK phosphorylation and activity in GH3 cells has been also studied. As to “in vivo” studies, western blot analysis revealed a significant decrease of phosphorylated AMPK alpha-subunit in pituitary homogenates of DEX-treated rats versus controls, suggesting reduced AMPK activity. In conclusion, our studies showed that AMPK has a role in regulating somatotroph function in normal rat pituitary and proliferation of pituitary adenomatous cells.
Literature
1.
go back to reference Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, Ruderman NB (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309–16313PubMedCrossRef Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, Ruderman NB (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309–16313PubMedCrossRef
2.
go back to reference Lim CT, Kola B, Korbonits M (2009) AMPK as a mediator of hormonal signalling. J Mol Endocrinol 44:87–97PubMedCrossRef Lim CT, Kola B, Korbonits M (2009) AMPK as a mediator of hormonal signalling. J Mol Endocrinol 44:87–97PubMedCrossRef
3.
go back to reference Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, Alessi DR, Hardie DG (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2:28PubMedCrossRef Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, Alessi DR, Hardie DG (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2:28PubMedCrossRef
4.
go back to reference Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13:2004–2008PubMedCrossRef Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13:2004–2008PubMedCrossRef
5.
go back to reference Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA (2005) The Ca2+/calmoldulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 280:29060–29066PubMedCrossRef Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA (2005) The Ca2+/calmoldulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 280:29060–29066PubMedCrossRef
6.
go back to reference Winder WW, Hardie DG (1996) Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol 270:E299–E304PubMed Winder WW, Hardie DG (1996) Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol 270:E299–E304PubMed
7.
go back to reference Young ME, Radda GK, Leighton B (1996) Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR–an activator of AMP-activated protein kinase. FEBS Lett 382:43–47PubMedCrossRef Young ME, Radda GK, Leighton B (1996) Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR–an activator of AMP-activated protein kinase. FEBS Lett 382:43–47PubMedCrossRef
8.
go back to reference Towler MC, Hardie GD (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328–341PubMedCrossRef Towler MC, Hardie GD (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328–341PubMedCrossRef
9.
go back to reference Steinberg GR, Jorgensen SB (2007) The AMP-activated protein kinase: role in regulation of skeletal muscle metabolism and insulin sensitivity. Mini Rev Med Chem 7:521–528CrossRef Steinberg GR, Jorgensen SB (2007) The AMP-activated protein kinase: role in regulation of skeletal muscle metabolism and insulin sensitivity. Mini Rev Med Chem 7:521–528CrossRef
10.
go back to reference Locatelli V, Torsello A (2005) Pyruvate and satiety: can we fool the brain? Endocrinology 146:1–2PubMedCrossRef Locatelli V, Torsello A (2005) Pyruvate and satiety: can we fool the brain? Endocrinology 146:1–2PubMedCrossRef
11.
go back to reference Josie M, Evans M (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305CrossRef Josie M, Evans M (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305CrossRef
12.
go back to reference Motoshima H, Goldstein BJ, Igata M, Araki E (2006) AMPK and cell proliferation–AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574:63–71PubMedCrossRef Motoshima H, Goldstein BJ, Igata M, Araki E (2006) AMPK and cell proliferation–AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574:63–71PubMedCrossRef
13.
go back to reference Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273PubMedCrossRef Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273PubMedCrossRef
14.
go back to reference Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, Barredo JC (2007) Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 6:46–58PubMedCrossRef Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, Barredo JC (2007) Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 6:46–58PubMedCrossRef
15.
go back to reference Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Villet B, Thompson CB (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745–6752PubMedCrossRef Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Villet B, Thompson CB (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745–6752PubMedCrossRef
16.
go back to reference Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A, Collins SP (2009) AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 8:733–741PubMedCrossRef Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A, Collins SP (2009) AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 8:733–741PubMedCrossRef
17.
go back to reference Corton JM, Gillespie JG, Hawley SA, Hardie DG (1995) 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229:558–565PubMedCrossRef Corton JM, Gillespie JG, Hawley SA, Hardie DG (1995) 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229:558–565PubMedCrossRef
18.
go back to reference Rattan R, Giri S, Singh AK, Singh I (2005) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280:39582–39593PubMedCrossRef Rattan R, Giri S, Singh AK, Singh I (2005) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280:39582–39593PubMedCrossRef
19.
go back to reference Gao Y, Zhou Y, Xu A, Wu D (2008) Effects of an AMP-activated protein kinase inhibitor, compound C, on adipogenic differentiation of 3T3–L1 cells. Biol Pharm Bull 31:1716–1722PubMedCrossRef Gao Y, Zhou Y, Xu A, Wu D (2008) Effects of an AMP-activated protein kinase inhibitor, compound C, on adipogenic differentiation of 3T3–L1 cells. Biol Pharm Bull 31:1716–1722PubMedCrossRef
20.
go back to reference Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2009) Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3E1 cells through endothelial NOS and BMP-2 expression. Am J Physiol Endocrinol Metab 296:139–146CrossRef Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2009) Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3E1 cells through endothelial NOS and BMP-2 expression. Am J Physiol Endocrinol Metab 296:139–146CrossRef
21.
go back to reference Iwasaki Y, Nishiyama M, Taguchi T, Kambayashi M, Asai M, Yoshida M, Nigawara T, Hashimoto K (2007) Activation of AMP-activated protein kinase stimulates proopiomelanocortin gene transcription in AtT20 corticotroph cells. Am J Physiol Endocrinol Metab 292:E1899–E1905PubMedCrossRef Iwasaki Y, Nishiyama M, Taguchi T, Kambayashi M, Asai M, Yoshida M, Nigawara T, Hashimoto K (2007) Activation of AMP-activated protein kinase stimulates proopiomelanocortin gene transcription in AtT20 corticotroph cells. Am J Physiol Endocrinol Metab 292:E1899–E1905PubMedCrossRef
22.
go back to reference Lu M, Tang Q, Olefsky JM, Mellon PL, Webster NJ (2008) Adiponectin activates adenosine monophosphate-activated protein kinase and decreases luteinizing hormone secretion in LβT2 gonadotropes. Mol Endocrinol 22:760–771PubMedCrossRef Lu M, Tang Q, Olefsky JM, Mellon PL, Webster NJ (2008) Adiponectin activates adenosine monophosphate-activated protein kinase and decreases luteinizing hormone secretion in LβT2 gonadotropes. Mol Endocrinol 22:760–771PubMedCrossRef
23.
go back to reference Müller EE, Locatelli V, Cocchi D (1999) Neuroendocrine control of growth hormone secretion. Physiol Rev 79:511–607PubMed Müller EE, Locatelli V, Cocchi D (1999) Neuroendocrine control of growth hormone secretion. Physiol Rev 79:511–607PubMed
24.
go back to reference Tulipano G, Soldi D, Bagnasco M, Culler MD, Taylor JE, Cocchi D, Giustina A (2002) Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143:1218–1224PubMedCrossRef Tulipano G, Soldi D, Bagnasco M, Culler MD, Taylor JE, Cocchi D, Giustina A (2002) Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143:1218–1224PubMedCrossRef
25.
go back to reference Miller M, Chen S, Woodliff J, Kansra S (2008) Curcumin (deferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells. Endocrinology 149:4158–4167PubMedCrossRef Miller M, Chen S, Woodliff J, Kansra S (2008) Curcumin (deferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells. Endocrinology 149:4158–4167PubMedCrossRef
26.
go back to reference Conejo R, Lorenzo M (2001) Insulin signaling leading to proliferation, survival and membrane ruffling in C2C12 myoblats. J Cell Physiol 187:96–108PubMedCrossRef Conejo R, Lorenzo M (2001) Insulin signaling leading to proliferation, survival and membrane ruffling in C2C12 myoblats. J Cell Physiol 187:96–108PubMedCrossRef
27.
go back to reference Tulipano G, Spano PF, Cocchi D (2008) Effects of olanzapine on glucose transport, proliferation and survival in C2C12 myoblasts. Mol Cell Endocrinol 292:42–49PubMedCrossRef Tulipano G, Spano PF, Cocchi D (2008) Effects of olanzapine on glucose transport, proliferation and survival in C2C12 myoblasts. Mol Cell Endocrinol 292:42–49PubMedCrossRef
28.
go back to reference Girnita L, Wang M, Xie Y, Nilsson G, Dricu A, Wejde J, Larsson O (2000) Inhibition of N-linked glycosylation downregulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing-’s sarcoma cells: therapeutic implications. Anticancer Drug Des 15:67–72PubMed Girnita L, Wang M, Xie Y, Nilsson G, Dricu A, Wejde J, Larsson O (2000) Inhibition of N-linked glycosylation downregulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing-’s sarcoma cells: therapeutic implications. Anticancer Drug Des 15:67–72PubMed
29.
go back to reference Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Ogura T, Lavin MF, Esumi H (2004) IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem Biophys Res Commun 324:986–992PubMedCrossRef Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Ogura T, Lavin MF, Esumi H (2004) IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem Biophys Res Commun 324:986–992PubMedCrossRef
30.
go back to reference Wehrenberg WB, Bergman PJ, Stagg L, Ndon J, Giustina A (1990) Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology 127:2705–2708PubMedCrossRef Wehrenberg WB, Bergman PJ, Stagg L, Ndon J, Giustina A (1990) Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology 127:2705–2708PubMedCrossRef
31.
go back to reference Tulipano G, Rossi E, Culler MD, Taylor JE, Bonadonna S, Locatelli V, Cocchi D, Giustina A (2005) The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat. Regul Pept 125:85–92PubMedCrossRef Tulipano G, Rossi E, Culler MD, Taylor JE, Bonadonna S, Locatelli V, Cocchi D, Giustina A (2005) The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat. Regul Pept 125:85–92PubMedCrossRef
32.
go back to reference Tulipano G, Taylor JE, Halem HA, Datta R, Dong JZ, Culler MD, Bianchi I, Cocchi D, Giustina A (2007) Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Pituitary 10:267–274PubMedCrossRef Tulipano G, Taylor JE, Halem HA, Datta R, Dong JZ, Culler MD, Bianchi I, Cocchi D, Giustina A (2007) Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Pituitary 10:267–274PubMedCrossRef
33.
go back to reference Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717–797PubMedCrossRef Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717–797PubMedCrossRef
34.
go back to reference Davies SP, Helps NR, Cohen PT, Hardie DG (1995) 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C{alpha} and native bovine protein phosphatase-2AC. FEBS Lett 377:421–425PubMedCrossRef Davies SP, Helps NR, Cohen PT, Hardie DG (1995) 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C{alpha} and native bovine protein phosphatase-2AC. FEBS Lett 377:421–425PubMedCrossRef
35.
go back to reference Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, Feltrin D, Igreja SC, Ajodha S, Harvey-White J, Kunos G, Müller B, Pralong F, Aubert G, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB, Korbonits M (2008) AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J 22:1673–1683CrossRef Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, Feltrin D, Igreja SC, Ajodha S, Harvey-White J, Kunos G, Müller B, Pralong F, Aubert G, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB, Korbonits M (2008) AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J 22:1673–1683CrossRef
36.
go back to reference Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev/Cancer 8:915–928CrossRef Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev/Cancer 8:915–928CrossRef
37.
go back to reference Yamasaki H, Prager D, Gebremedhin S, Moise L, Melmed S (1991) Binding and action of insulin-like growth factor-1 in pituitary tumor cells. Endocrinology 128:857–862PubMedCrossRef Yamasaki H, Prager D, Gebremedhin S, Moise L, Melmed S (1991) Binding and action of insulin-like growth factor-1 in pituitary tumor cells. Endocrinology 128:857–862PubMedCrossRef
38.
go back to reference Ceda GP, Fielder PJ, Donovan SM, Rosenfeld RG, Hoffman AR (1992) Regulation of insulin-like growth factor binding protein expression by thyroid hormone in rat GH3 pituitary tumor cells. Endocrinology 130:1483–1489PubMedCrossRef Ceda GP, Fielder PJ, Donovan SM, Rosenfeld RG, Hoffman AR (1992) Regulation of insulin-like growth factor binding protein expression by thyroid hormone in rat GH3 pituitary tumor cells. Endocrinology 130:1483–1489PubMedCrossRef
39.
go back to reference Castillo AI, Aranda A (1997) Differential regulation of pituitary specific gene expression by insulin-like growth factor-1 in rat pituitary GH4C1 and GH3 cells. Endocrinology 138:5442–5451PubMedCrossRef Castillo AI, Aranda A (1997) Differential regulation of pituitary specific gene expression by insulin-like growth factor-1 in rat pituitary GH4C1 and GH3 cells. Endocrinology 138:5442–5451PubMedCrossRef
40.
go back to reference Wang L, Yang H, Adamo ML (2000) Glucose stravation reduces IGF-1 mRNA in tumor cells: evidence for an effect on mRNA stability. Biochem Biophys Res Comm 269:336–346PubMedCrossRef Wang L, Yang H, Adamo ML (2000) Glucose stravation reduces IGF-1 mRNA in tumor cells: evidence for an effect on mRNA stability. Biochem Biophys Res Comm 269:336–346PubMedCrossRef
41.
go back to reference Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMPK-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174PubMed Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMPK-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174PubMed
42.
go back to reference Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509–1517PubMedCrossRef Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509–1517PubMedCrossRef
43.
go back to reference Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts SW, Casanueva PP, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148PubMedCrossRef Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts SW, Casanueva PP, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148PubMedCrossRef
Metadata
Title
AMP-activated protein kinase regulates normal rat somatotroph cell function and growth of rat pituitary adenomatous cells
Authors
Giovanni Tulipano
Michela Giovannini
Maurizio Spinello
Valeria Sibilia
Andrea Giustina
Daniela Cocchi
Publication date
01-09-2011
Publisher
Springer US
Published in
Pituitary / Issue 3/2011
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-010-0288-6

Other articles of this Issue 3/2011

Pituitary 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.